BERLIN and SEATTLE, Oct. 10, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN:DE000A0BVT96) today announced the formation of its Colorectal Cancer Medical Advisory board and the appointment of its first four members. The board will advise Epigenomics on important aspects of the clinical development and commercialization process of the colorectal cancer screening test in the U.S. The inaugural meeting of the board will be held on October 12, 2007 in Philadelphia, PA, U.S.A.
